SNOA Stock - Sonoma Pharmaceuticals, Inc.
Unlock GoAI Insights for SNOA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $14.29M | $12.73M | $13.27M | $12.63M | $18.63M |
| Gross Profit | $5.46M | $4.75M | $4.48M | $3.99M | $6.56M |
| Gross Margin | 38.2% | 37.3% | 33.7% | 31.6% | 35.2% |
| Operating Income | $-3,710,000 | $-4,701,000 | $-4,570,000 | $-5,887,000 | $-3,449,000 |
| Net Income | $-3,457,000 | $-4,835,000 | $-5,151,000 | $-5,086,000 | $-3,950,000 |
| Net Margin | -24.2% | -38.0% | -38.8% | -40.3% | -21.2% |
| EPS | $-2.79 | $-5.32 | $-15.18 | $-19.17 | $-23.65 |
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.
Visit WebsiteEarnings History & Surprises
SNOAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 4, 2026 | — | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.31 | $-0.13 | +58.1% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.51 | $-0.37 | +27.5% | ✓ BEAT |
Q2 2025 | Jun 17, 2025 | $-0.73 | $-0.15 | +79.5% | ✓ BEAT |
Q1 2025 | Feb 5, 2025 | $-0.80 | $-0.59 | +26.3% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-1.00 | $-0.59 | +41.0% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.06 | $-1.40 | -2233.3% | ✗ MISS |
Q2 2024 | Jun 17, 2024 | $-3.41 | $-1.40 | +58.9% | ✓ BEAT |
Q1 2024 | Feb 8, 2024 | $-0.21 | $-1.20 | -471.4% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-0.24 | $-4.00 | -1566.7% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-2.40 | $-5.80 | -141.7% | ✗ MISS |
Q2 2023 | Jun 21, 2023 | — | $-4.60 | — | — |
Q1 2023 | Feb 14, 2023 | — | $-10.00 | — | — |
Q4 2022 | Nov 14, 2022 | — | $-3.80 | — | — |
Q3 2022 | Aug 11, 2022 | — | $-5.80 | — | — |
Q3 2022 | Jul 13, 2022 | — | $-19.00 | — | — |
Q1 2022 | Feb 11, 2022 | — | $-6.20 | — | — |
Q4 2021 | Nov 15, 2021 | — | $-0.80 | — | — |
Q3 2021 | Aug 16, 2021 | — | $-10.40 | — | — |
Q3 2021 | Jul 14, 2021 | — | $-32.80 | — | — |
Latest News
Sonoma Pharmaceuticals And Partner MicroSafe Care Receive Australian Therapeutic Goods Administration Approval For Its Nanocyn Advanced Disinfectant & Sanitizer
📈 PositiveSonoma Pharmaceuticals Q2 EPS $(0.32) Misses $(0.31) Estimate, Sales $5.604M Beat $4.261M Estimate
➖ NeutralSonoma Pharmaceuticals Terminates EVP And COO Bruce Thornton For Cause, Effective October 18, 2025
📉 NegativeSonoma Pharmaceuticals Highlights FDA Cosmetic Product Facility Registration, Microcyn-Based Cosmetic Product Listing Under MoCRA
📈 PositiveSonoma Pharmaceuticals Enters At Market Issuance Sales Agreement With Ladenburg; To Pay 3% Commission To Ladenburg On Share Sales
➖ NeutralFrequently Asked Questions about SNOA
What is SNOA's current stock price?
What is the analyst price target for SNOA?
What sector is Sonoma Pharmaceuticals, Inc. in?
What is SNOA's market cap?
Does SNOA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SNOA for comparison